Drug Profile
Anti-inducible T-cell costimulator therapeutic - Bristol Myers Squibb
Alternative Names: Anti-ICOS - Bristol Myers SquibbLatest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Inducible T-cell co-stimulator protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Cancer in Unknown
- 16 Nov 2017 Phase-I clinical trials in Cancer before November 2017 (Bristol-Myers Squibb pipeline, November 2017)